All Stories

  1. Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson’s Disease: INSIGHTS Study
  2. An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders
  3. PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study
  4. Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
  5. Small-expanded allele spinocerebellar ataxia 17: imaging and phenotypic variability
  6. Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden [Corrigendum]
  7. <p>Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden</p>
  8. Pathological findings in a patient with alpha-synuclein p.A53T and familial Parkinson's disease
  9. Changes of olfactory tract in Parkinson’s disease: a DTI tractography study
  10. Levetiracetam-responsive belly dancer’s syndrome in a case of progressive supranuclear palsy
  11. Coverage of the requirements of first and second level stroke unit in Italy
  12. Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
  13. Correction to: Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study
  14. Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson’s Disease: Pulsatile versus Continuous Dopaminergic Stimulation
  15. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
  16. Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?
  17. Hippocampal epileptogenesis in autoimmune encephalitis
  18. T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson's disease
  19. Substantia nigra hyperechogenicity in essential tremor and Parkinson's disease: a longitudinal study
  20. Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm
  21. Incidence and prevalence of Parkinson’s disease in the Italian region of Umbria: a population-based study using healthcare administrative databases
  22. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study
  23. Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
  24. Long-term follow-up in pediatric patients with paroxysmal hypothermia (Shapiro's syndrome)
  25. Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences
  26. Levodopa after 60 years: still a gold standard drug, with so many formulations to use.
  27. Levodopa-responsive breathing discomfort in Parkinson’s disease patients
  28. Correction to: The Italian Dystonia Registry: rationale, design and preliminary findings
  29. Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study
  30. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients
  31. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
  32. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up
  33. The Italian Dystonia Registry: rationale, design and preliminary findings
  34. Movement disorders in 2016: from genes to phenotypes
  35. A53T in a parkinsonian family: a clinical update of the SNCA phenotypes
  36. Imaging synucleinopathies
  37. Prognostic factors in children with PRES and hematologic diseases
  38. Magnetization transfer MRI in dementia disorders, Huntington's disease and parkinsonism
  39. The validation of an Italian version of the Freezing of Gait Questionnaire
  40. Diagnostic Accuracy of Parkinson Disease by Support Vector Machine (SVM) Analysis of 123I-FP-CIT Brain SPECT Data
  41. Subclinical Visuospatial Impairment in Parkinson’s Disease: The Role of Basal Ganglia and Limbic System
  42. Shapiro's syndrome: Defining the clinical spectrum of the spontaneous paroxysmal hypothermia syndrome
  43. Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
  44. Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study
  45. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
  46. Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
  47. Complexity of Motor Sequences and Cortical Reorganization in Parkinson's Disease: A Functional MRI Study
  48. Cerebrospinal fluid biomarkers in Parkinson disease
  49. The validity and reliability of the Italian Olfactory Identification Test (IOIT) in healthy subjects and in Parkinson's disease patients
  50. Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale
  51. Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease Patients
  52. Clinical Aspects and Management of Levodopa-Induced Dyskinesia
  53. Recurrent hypothermia with hyperhidrosis in two siblings: familial Shapiro syndrome variant
  54. Levodopa-induced breathing, cognitive and behavioral changes in Parkinson’s disease
  55. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias
  56. Levetiracetam in brain ischemia: Clinical implications in neuroprotection and prevention of post-stroke epilepsy
  57. A novel spinocerebellar ataxia type 15 family with involuntary movements and cognitive decline
  58. Decreased Contralateral Putamen [123I]FP-CIT SPECT Uptake in Hyperglycemic Hemichorea-Hemiballismus
  59. Ictal Epileptic Headache Mimicking Status Migrainosus: EEG and DWI-MRI Findings
  60. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
  61. Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis
  62. A magnetization transfer study of mild and advanced Parkinson’s disease
  63. Hyperhomocysteinemia recurrence in levodopa‐treated Parkinson’s disease patients
  64. Vomiting due to intravenous levetiracetam in a case of Creutzfeldt–Jakob disease
  65. A young patient with type C multiple system atrophy and hereditary hemochromatosis
  66. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies
  67. Hot water epilepsy and Mccune–Albright syndrome: A case report
  68. Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy
  69. Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
  70. Nerve growth factor and brain-derived neurotrophic factor: potential targets for migraine treatment?
  71. Acute dystonia induced by the combination of midodrine and perphenazine
  72. Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide
  73. CT angiography versus colour-Doppler US in acute dissection of the vertebral artery
  74. Occipital pseudoaneurysm as a complication of extension channel placement for DBS in Parkinson's disease
  75. Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: Results of a population-based study
  76. Educational Approach on Stroke Training in Europe
  77. Characteristics of Delayed Admission to Stroke Unit
  78. Efficacy of Thrombolytic (rt-PA) Therapy in Old Stroke Patients: The Perugia Stroke Unit Experience
  79. Multimodal Use of Computed Tomography in Early Acute Stroke, Part 1
  80. First Chieti Stroke Meeting: Preface
  81. Multimodal Use of Computed Tomography in Early Acute Stroke, Part 2
  82. Secondary Prevention of Cardioembolic Stroke: Oldest and Newest Promises
  83. Subtotal corpus callosum agenesis with recurrent hyperhidrosis-hypothermia (Shapiro syndrome)
  84. Cardiac pacing: atrial fibrillation may go unrecognised
  85. A case of vertebrobasilar stroke during oxygen-ozone therapy
  86. Assessment of tremor: a new computerised tool for clinical practice
  87. Neurovascular territory involved in different etiological subtypes of ischemic stroke in the Perugia Stroke Registry
  88. Magnetization transfer changes of grey and white matter in Parkinson's disease
  89. BRAIN CT-SCAN IN ACUTE STROKE PATIENTS: SILENT INFARCTS AND RELATION TO OUTCOME
  90. BRAIN CT SCAN IN ACUTE ISCHEMIC STROKE: EARLY SIGNS AND FUNCTIONAL OUTCOME
  91. Attivazione delle aree corticali motorie nel morbo di Parkinson Studio funzionale con risonanza magnetica
  92. Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group
  93. Studio funzionale RM delle aree motorie corticali nel morbo di Parkinson